Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 685509 in portal hypertension after first decompensation in cirrhosis
CTR20234147Phase 2Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of avenciguat in Cirrhosis, Portal Hypertension (PH), sponsored by Boehringer Ingelheim. Started Dec 2023; status: terminated.
02
Drugs
avenciguat
03
Conditions
CirrhosisPortal Hypertension (PH)
Beyond the preview
Go deeper on CTR20234147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20234147.